Consistent with these studies on pancreatic cancer and osteosarcoma [25, 35, 36], treatment with 25 μmol/L AR-A014418 for 72 hrs attenuated the relative transcriptional activity of NF-κB in 3 of 4 osteosarcoma cell lines, but not in hFOB1.19 osteoblast cells (Supplementary Figure S6B). The gene discussed is NFKB1; the disease is osteosarcoma.